BRAIN Biotech AG
XETRA:BNN
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
DE |
BRAIN Biotech AG
XETRA:BNN
|
61.2m EUR | -12.7 | ||
JP |
Shin-Etsu Chemical Co Ltd
TSE:4063
|
12.1T JPY | 24.4 | ||
US |
Sherwin-Williams Co
NYSE:SHW
|
77.1B USD | 32.8 | ||
US |
Ecolab Inc
NYSE:ECL
|
64.2B USD | 43.3 | ||
CH |
Sika AG
SIX:SIKA
|
42.2B CHF | 33.9 | ||
CH |
Givaudan SA
SIX:GIVN
|
36.4B CHF | 44 | ||
CN |
Wanhua Chemical Group Co Ltd
SSE:600309
|
279.8B CNY | -23.1 | ||
US |
Dupont De Nemours Inc
NYSE:DD
|
33.7B USD | 30.1 | ||
IN |
Asian Paints Ltd
NSE:ASIANPAINT
|
2.8T INR | 67 | ||
US |
PPG Industries Inc
NYSE:PPG
|
30.7B USD | 22.4 | ||
CH |
D
|
DSM-Firmenich AG
AEX:DSFIR
|
28.1B EUR | 49.6 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.